• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Long-Term Abnormalities of Lipid Profile After a Single Episode of Sepsis
Conclusions: Our study suggests that persistent derangements of lipid profile components for up to two years after sepsis may be associated with altered risk of atherosclerosis-related events among sepsis survivors.PMID:34869619 | PMC:PMC8634493 | DOI:10.3389/fcvm.2021.674248
Source: Atherosclerosis - December 6, 2021 Category: Cardiology Authors: Nicholas Felici Da Liu Josh Maret Mariana Restrepo Yuliya Borovskiy Jihane Hajj Wesley Chung Krzysztof Laudanski Source Type: research

Lipoprotein(a) and Cardiovascular Diseases 　- Revisited.
Lipoprotein(a) and Cardiovascular Diseases　- Revisited. Circ J. 2020 Apr 24;: Authors: Jang AY, Han SH, Sohn IS, Oh PC, Koh KK Abstract Two decades ago, it was recognized that lipoprotein(a) (Lp(a)) concentrations were elevated in patients with cardiovascular disease (CVD). However, the importance of Lp(a) was not strongly established due to a lack of both Lp(a)-lowering therapy and evidence that reducing Lp(a) levels improves CVD risk. Recent advances in clinical and genetic research have revealed the crucial role of Lp(a) in the pathogenesis of CVD. Mendelian randomization studies have shown that ...
Source: Circulation Journal - April 23, 2020 Category: Cardiology Authors: Jang AY, Han SH, Sohn IS, Oh PC, Koh KK Tags: Circ J Source Type: research

Lipoprotein(a) —It Is Risky, but What Do We Do About It?
AbstractPurpose of ReviewLipoprotein(a) [Lp(a)] is a pro-inflammatory, pro-thrombotic, and pro-atherogenic lipoprotein particle. Lp(a) binds and transports oxidized phospholipids in the bloodstream. It is one of the strongest genetic risk factors for coronary artery disease, stroke, and calcific aortic valve stenosis.Recent FindingsElevated Lp(a) levels, or hyperlipoproteinemia(a), is associated with cardiovascular outcomes even in high-risk individuals who achieve their low-density lipoprotein cholesterol target with statins. Lifestyle modification therapy and dietary supplements have little impact on plasma Lp(a) levels....
Source: Current Cardiovascular Risk Reports - September 29, 2018 Category: Cardiology Source Type: research

Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs Original Articles
Conclusions— In HPS2-THRIVE, the addition of extended-release niacin–laropiprant to statin-based therapy reduced quality of life–adjusted survival and increased hospital costs. Clinical Trial Registration— URL: http://clinicaltrials.gov. Unique identifier: NCT00461630.
Source: Circulation: Cardiovascular Quality and Outcomes - July 18, 2016 Category: Cardiology Authors: Kent, S., Haynes, R., Hopewell, J. C., Parish, S., Gray, A., Landray, M. J., Collins, R., Armitage, J., Mihaylova, B., on behalf of the HPS2-THRIVE Collaborative Group Tags: Cardiovascular Disease, Treatment, Cost-Effectiveness, Quality and Outcomes, Vascular Disease Original Articles Source Type: research

Cardiovascular highlights from non-cardiology journals
Niacin fails to prevent cardiovascular events Observational studies have consistently demonstrated that levels of LDL cholesterol directly correlate with cardiovascular risk while HDL levels are inversely related to cardiovascular risk. Niacin is known to reduce LDL levels and concurrently raise HDL levels. In the HPS2-THRIVE study, 25,673 patients with a background of vascular disease were randomized to receive 2 g of extended-release niacin and 40 mg of laropiprant (an anti-flushing agent) or a matching placebo daily. Prior to starting the study, in a run-in phase, background statin therapy was standardized wit...
Source: Heart - September 23, 2014 Category: Cardiology Authors: Bradley, S. M. Tags: Journal scan Source Type: research

Relationship of Lipoproteins to Cardiovascular Events The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial.BackgroundDuring a 3-year follow-up in 3,414 patients with established CV disease and low high-density lipoprotein cholesterol (HDL-C) levels, combined niacin + low-density lipoprotein cholesterol (LDL-C)–lowering therapy did not reduce CV events compared with LDL-C–lowering therapy alone.MethodsSubjects taking simvastatin and/or ez...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - October 14, 2013 Category: Cardiology Source Type: research

Relationship of Lipoproteins to Cardiovascular Events: The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial.Background: During a 3-year follow-up in 3,414 patients with established CV disease and low high-density lipoprotein cholesterol (HDL-C) levels, combined niacin + low-density lipoprotein cholesterol (LDL-C)–lowering therapy did not reduce CV events compared with LDL-C–lowering therapy alone.Methods: Subjects taking simvastatin and/o...
Source: Journal of the American College of Cardiology - August 2, 2013 Category: Cardiology Authors: John R. Guyton, April E. Slee, Todd Anderson, Jerome L. Fleg, Ronald B. Goldberg, Moti L. Kashyap, Santica M. Marcovina, Stephen D. Nash, Kevin D. O'Brien, William S. Weintraub, Ping Xu, Xue-Qiao Zhao, William E. Boden Tags: Cardiometabolic Risk Source Type: research

The Current State of Niacin in Cardiovascular Disease Prevention A Systematic Review and Meta-Regression
ConclusionsThe consensus perspective derived from available clinical data supports that niacin reduces CVD events and, further, that this may occur through a mechanism not reflected by changes in high-density lipoprotein cholesterol concentration.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 21, 2013 Category: Cardiology Source Type: research

The Current State of Niacin in Cardiovascular Disease Prevention: A Systematic Review and Meta-Regression
Conclusions: The consensus perspective derived from available clinical data supports that niacin reduces CVD events and, further, that this may occur through a mechanism not reflected by changes in high-density lipoprotein cholesterol concentration.
Source: Journal of the American College of Cardiology - December 26, 2012 Category: Cardiology Authors: Paul M. Lavigne, Richard H. Karas Tags: Cardiometabolic Risk Source Type: research